查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
支氣管炎治療藥的全球市場 (2022～2030年):成長、未來展望、競爭分析
市場調查報告書
商品編碼
1162481

支氣管炎治療藥的全球市場 (2022～2030年):成長、未來展望、競爭分析

Bronchitis Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 120 Pages | 商品交期: 最快1-2個工作天內

價格

支氣管炎治療藥的市場規模，2021年為35億970萬美元，預計從2022年～到2030年的預測期間中以4.9％的年複合成長率成長。

該市場，由於含標靶藥物等強力的產品平台，支氣管炎的盛行率和治療、診斷的認知度上升，預計在整個預測期內顯示階段性的成長。持續性R&D預期支撐市場整體成長。

本報告提供全球支氣管炎治療藥的市場調查，市場概要，市場成長的各種影響因素分析，市場規模的變化、預測，各種區分、各地區/主要國家的明細，主要企業簡介等彙整資訊。

目錄

第1章 序文

第2章 摘要整理

第3章 支氣管炎治療藥市場:事業預測、市場動態

  • 世界市場規模:2020年～2030年
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要的機會
  • 促進因素、阻礙因素的影響分析
  • See-Saw分析
  • 波特的五力分析
  • PESTEL分析

第4章 支氣管炎治療藥市場:各類藥物

  • 市場概要
  • 成長、收益分析
  • 市場分類
    • 止咳、祛痰藥
    • 支氣管擴張藥
    • β腎上腺素促效劑
    • 全身性皮質類固醇
    • 吸入皮質類固醇
    • 磷酸二酯酶亞型四抑制劑
    • 止痛藥
    • 抗生素

第5章 北美的支氣管炎治療藥市場

  • 市場概要
  • 支氣管炎治療藥市場:各類藥物
  • 支氣管炎治療藥市場:各地區

第6章 英國及EU的支氣管炎治療藥市場

  • 市場概要
  • 支氣管炎治療藥市場:各類藥物
  • 支氣管炎治療藥市場:各地區

第7章 亞太地區的支氣管炎治療藥市場

  • 市場概要
  • 支氣管炎治療藥市場:各類藥物
  • 支氣管炎治療藥市場:各地區

第8章 南美的支氣管炎治療藥市場

  • 市場概要
  • 支氣管炎治療藥市場:各類藥物
  • 支氣管炎治療藥市場:各地區

第9章 中東、非洲的支氣管炎治療藥市場

  • 市場概要
  • 支氣管炎治療藥市場:各類藥物
  • 支氣管炎治療藥市場:各地區

第10章 企業簡介

  • Advanced Inhalation Therapies(AIT)Ltd.
  • AstraZeneca Plc
  • DBV Technologies SA
  • F. Hoffmann-La Roche Ltd.
  • Han Wha Pharma Co. Ltd.
  • Kyorin Pharmaceutical Co Ltd.
  • Merck & Co.
  • Mucosis BV
  • Orbis Biosciences, Inc.
  • Therabron Therapeutics, Inc.
  • GlaxoSmithKline plc
  • Chong Kun Dang Pharmaceutical
  • ONY Biotech Inc.
  • Genentech, Inc.
  • Daewon Pharm Co. Ltd.
Product Code: 138656-08-22

Industry Outlook

Bronchitis treatment market accounted for a market value of US$ 3,509.7 Mn in 2021 and is projected to grow at a CAGR of 4.9% during the forecast period from 2022 to 2030. Bronchitis treatment market is growing gradually throughout the forecast period due to strong product pipeline equipped with target-specific drugs, and rising prevalence & awareness related to the treatment & diagnosis of bronchitis. The major cause of bronchitis is frequent cigarette smoking coupled with exposure to air-pollutants. Thus, overall growth of global bronchitis treatment is significant and expected to maintain its growth throughout the forecast year with the help of upcoming drugs currently present under trials.

Continuous research & development in the field of bronchitis treatment expected to bring novel drugs in the market & ultimately assist the overall growth

During the forecast period from 2022 to 2030, phospodiesterase-4inhibitors identified as the fastest growing segment due to major factors such as Roflumilast are beneficial in chronic bronchitis to decrease exacerbations & relieve dyspnea, and physicians treat chronic bronchitis on priority as its more complex compared to acute bronchitis. Roflumilast also plays key role in improving the lung function and assists recovery of patients. Thus, novel drugs entering in the market will increase the growth of overall bronchitis treatment market, as there is huge market demand for target-specific drugs in the market.

Increasing prevalence & awareness related to the bronchitis in Asia Pacific makes it the fastest growing region throughout the forecast period

The Asia Pacific will grow significantly throughout the forecast period from 2022 to 2030, the key factors responsible for growth of bronchitis treatment market in this region are rising prevalence of bronchitis due to high level of air-pollution & smoking population, and increasing awareness and accessibility related to bronchitis treatment. There are several awareness campaigns carried out by government and non-government organizations in developing countries of Asia Pacific such as China, India, Indonesia, and Thailand due to which bronchitis treatment market is growing significantly in this region. China & India have highest population suffering with bronchitis that mainly caused due to air-pollution and huge cigarette smoking population. According to World Health Organization (WHO), it has been recorded that in Asia around one third or 2.2 million of the world's 7 million premature deaths occur due to respiratory disorders caused due to air-pollution each year.

The key manufacturers present in the market reported based on product portfolio, current market updates, financial information, and key strategies. This report also include attractive investment proposition studied with the aid of PESTEL analysis, which based on detailed geographical research. Major companies studied in the overall report are AstraZeneca Plc, DBV Technologies SA, F. Hoffmann-La Roche Ltd., Han Wha Pharma Co. Ltd., and Mucosis BV among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Bronchitis Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Bronchitis Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

  • Antitussives/ Expectorants
  • Bronchodilators
  • Beta-adrenergic Agonist
  • Systemic Corticosteroids
  • Inhaled Corticosteroids
  • Phosphodiesterase-4 Inhibitors
  • Analgesics
  • Antibiotics

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Bronchitis Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Bronchitis Treatment market?
  • Which is the largest regional market for Bronchitis Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Bronchitis Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Bronchitis Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Bronchitis Treatment Market
  • 2.2. Global Bronchitis Treatment Market, By Drug Class, 2021 (US$ Million)
  • 2.3. Global Bronchitis Treatment Market, By Geography, 2021 (US$ Million)
  • 2.4. Impact of Covid 19
  • 2.5. Attractive Investment Proposition by Geography, 2021
  • 2.6. Competitive Analysis
    • 2.6.1. Market Positioning of Key Bronchitis Treatment Market Vendors
    • 2.6.2. Strategies Adopted by Bronchitis Treatment Market Vendors
    • 2.6.3. Key Industry Strategies

3. Bronchitis Treatment Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Bronchitis Treatment Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Antitussives/ Expectorants
    • 4.3.2. Bronchodilators
    • 4.3.3. Beta-adrenergic Agonist
    • 4.3.4. Systemic Corticosteroids
    • 4.3.5. Inhaled Corticosteroids
    • 4.3.6. Phosphodiesterase-4 Inhibitors
    • 4.3.7. Analgesics
    • 4.3.8. Antibiotics

5. North America Bronchitis Treatment Market, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 5.3.Bronchitis Treatment Market: By Region, 2020-2030, USD (Million)
    • 5.3.1.North America
      • 5.3.1.1. U.S.
      • 5.3.1.2. Canada
      • 5.3.1.3. Rest of North America

6. UK and European Union Bronchitis Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 6.3.Bronchitis Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.UK and European Union
      • 6.3.1.1. UK
      • 6.3.1.2. Germany
      • 6.3.1.3. Spain
      • 6.3.1.4. Italy
      • 6.3.1.5. France
      • 6.3.1.6. Rest of Europe

7. Asia Pacific Bronchitis Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 7.3.Bronchitis Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.Asia Pacific
      • 7.3.1.1. China
      • 7.3.1.2. Japan
      • 7.3.1.3. India
      • 7.3.1.4. Australia
      • 7.3.1.5. South Korea
      • 7.3.1.6. Rest of Asia Pacific

8. Latin America Bronchitis Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 8.3.Bronchitis Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Latin America
      • 8.3.1.1. Brazil
      • 8.3.1.2. Mexico
      • 8.3.1.3. Rest of Latin America

9. Middle East and Africa Bronchitis Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 9.3.Bronchitis Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Middle East and Africa
      • 9.3.1.1. GCC
      • 9.3.1.2. Africa
      • 9.3.1.3. Rest of Middle East and Africa

10. Company Profile

  • 10.1. Advanced Inhalation Therapies (AIT) Ltd.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Initiatives
  • 10.2. AstraZeneca Plc
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Initiatives
  • 10.3. DBV Technologies SA
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Portfolio
    • 10.3.4. Strategic Initiatives
  • 10.4. F. Hoffmann-La Roche Ltd.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Initiatives
  • 10.5. Han Wha Pharma Co. Ltd.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Initiatives
  • 10.6. Kyorin Pharmaceutical Co Ltd.
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
    • 10.6.4. Strategic Initiatives
  • 10.7. Merck & Co.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Portfolio
    • 10.7.4. Strategic Initiatives
  • 10.8. Mucosis BV
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Portfolio
    • 10.8.4. Strategic Initiatives
  • 10.9. Orbis Biosciences, Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Portfolio
    • 10.9.4. Strategic Initiatives
  • 10.10. Therabron Therapeutics, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Initiatives
  • 10.11. GlaxoSmithKline plc
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Portfolio
    • 10.11.4. Strategic Initiatives
  • 10.12. Chong Kun Dang Pharmaceutical
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Portfolio
    • 10.12.4. Strategic Initiatives
  • 10.13. ONY Biotech Inc.
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Portfolio
    • 10.13.4. Strategic Initiatives
  • 10.14. Genentech, Inc.
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Portfolio
    • 10.14.4. Strategic Initiatives
  • 10.15. Daewon Pharm Co. Ltd.
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Portfolio
    • 10.15.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 2 North America Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 3 UK and European Union Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 4 Asia Pacific Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 5 Latin America Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 6 Middle East and Africa Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Bronchitis Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Bronchitis Treatment Market: Quality Assurance
  • FIG. 5 Global Bronchitis Treatment Market, By Drug Class, 2021
  • FIG. 6 Global Bronchitis Treatment Market, By Geography, 2021
  • FIG. 7 Global Bronchitis Treatment Market, By Drug Class, 2021 Vs 2030, %
  • FIG. 8 U.S. Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 9 Canada Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 10 Rest of North America Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 11 UK Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Germany Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 Spain Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 Italy Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 France Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Rest of Europe Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 China Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 Japan Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 India Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 Australia Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 South Korea Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 Rest of Asia Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Brazil Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 Mexico Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Latin America Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 GCC Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Africa Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Middle East and Africa Bronchitis Treatment Market (US$ Million), 2020 - 2030